Literature DB >> 33143491

Relationship between Comorbid Drug Use Disorders, Affective Disorders, and Current Smoking.

Maria A Parker1,2, Andrea C Villanti1.   

Abstract

OBJECTIVE: This study aimed to identify subgroups of adults based on comorbid psychiatric disorders and to examine the relationship with current smoking. Method: The National Epidemiologic Survey on Alcohol and Related Conditions-III, 2012-2013, sampled, recruited, and assessed 36,309 adults, with interviews on drug use and other characteristics. The Alcohol Use Disorder and Associated Disabilities Interview Schedule DSM-5 Version (AUDADIS-5) was used to identify psychiatric conditions. Latent class models were developed based on various psychiatric diagnoses. Multinomial logistic regression estimated the significance of covariates in predicting class membership.
Results: Four latent classes optimally distinguished the population: no comorbid conditions (63%), comorbid affective disorders (16%), those with alcohol use disorder (AUD; 17%), and a highly comorbid subgroup (i.e., co-occurring affective and drug use disorders; 4%). Current smoking was about twice as prevalent in the classes defined by psychiatric conditions compared to the group with no comorbid conditions. The highly comorbid class was more likely to be current smokers than the comorbid affective disorders class and the AUD class. Furthermore, the highly comorbid class was younger and had lower income, and the AUD class had a higher proportion of males than the other classes. Conclusions: Cigarette smoking was higher in the nearly 40% of respondents characterized by psychiatric disorders, particularly those with drug use disorders. Correlates of membership in these classes were consistent with known vulnerabilities for smoking, highlighting the need for mental health interventions and future research to explicitly address tobacco cessation in clinical settings based on psychiatric diagnoses.

Entities:  

Keywords:  Latent class analysis; epidemiology; psychiatric; smoking; tobacco

Mesh:

Substances:

Year:  2020        PMID: 33143491      PMCID: PMC8269958          DOI: 10.1080/10826084.2020.1840591

Source DB:  PubMed          Journal:  Subst Use Misuse        ISSN: 1082-6084            Impact factor:   2.164


  39 in total

1.  Cigarette smoking among those with mental disorders in the US population: 2012-2013 update.

Authors:  Philip H Smith; Mohammad Chhipa; Josef Bystrik; Jordan Roy; Renee D Goodwin; Sherry A McKee
Journal:  Tob Control       Date:  2018-10-30       Impact factor: 7.552

2.  Nosologic Comparisons of DSM-IV and DSM-5 Alcohol and Drug Use Disorders: Results From the National Epidemiologic Survey on Alcohol and Related Conditions-III.

Authors:  Risë B Goldstein; S Patricia Chou; Sharon M Smith; Jeesun Jung; Haitao Zhang; Tulshi D Saha; Roger P Pickering; W June Ruan; Boji Huang; Bridget F Grant
Journal:  J Stud Alcohol Drugs       Date:  2015-05       Impact factor: 2.582

3.  Patterns of polydrug use in Great Britain: findings from a national household population survey.

Authors:  Gillian W Smith; Michael Farrell; Brendan P Bunting; James E Houston; Mark Shevlin
Journal:  Drug Alcohol Depend       Date:  2010-09-21       Impact factor: 4.492

4.  Trends in smoking among adults with mental illness and association between mental health treatment and smoking cessation.

Authors:  Benjamin Lê Cook; Geoff Ferris Wayne; E Nilay Kafali; Zimin Liu; Chang Shu; Michael Flores
Journal:  JAMA       Date:  2014-01-08       Impact factor: 56.272

5.  The Alcohol Use Disorder and Associated Disabilities Interview Schedule-5 (AUDADIS-5): reliability of substance use and psychiatric disorder modules in a general population sample.

Authors:  Bridget F Grant; Rise B Goldstein; Sharon M Smith; Jeesun Jung; Haitao Zhang; Sanchen P Chou; Roger P Pickering; Wenjun J Ruan; Boji Huang; Tulshi D Saha; Christina Aivadyan; Eliana Greenstein; Deborah S Hasin
Journal:  Drug Alcohol Depend       Date:  2014-12-08       Impact factor: 4.492

6.  Persistence of extra-medical prescription pain reliever use and alcohol involvement among United States 12-20 year olds.

Authors:  Maria A Parker
Journal:  Exp Clin Psychopharmacol       Date:  2019-03-14       Impact factor: 3.157

7.  Psychiatric Disorders Among Patients Seeking Treatment for Co-Occurring Chronic Pain and Opioid Use Disorder.

Authors:  Declan T Barry; Christopher J Cutter; Mark Beitel; Robert D Kerns; Christopher Liong; Richard S Schottenfeld
Journal:  J Clin Psychiatry       Date:  2016-10       Impact factor: 4.384

8.  21st-century hazards of smoking and benefits of cessation in the United States.

Authors:  Prabhat Jha; Chinthanie Ramasundarahettige; Victoria Landsman; Brian Rostron; Michael Thun; Robert N Anderson; Tim McAfee; Richard Peto
Journal:  N Engl J Med       Date:  2013-01-24       Impact factor: 91.245

Review 9.  Treatment of smokers with co-occurring disorders: emphasis on integration in mental health and addiction treatment settings.

Authors:  Sharon M Hall; Judith J Prochaska
Journal:  Annu Rev Clin Psychol       Date:  2009       Impact factor: 18.561

10.  Epidemiology of DSM-5 Drug Use Disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions-III.

Authors:  Bridget F Grant; Tulshi D Saha; W June Ruan; Risë B Goldstein; S Patricia Chou; Jeesun Jung; Haitao Zhang; Sharon M Smith; Roger P Pickering; Boji Huang; Deborah S Hasin
Journal:  JAMA Psychiatry       Date:  2016-01       Impact factor: 21.596

View more
  2 in total

1.  COVID-related distress, mental health, and substance use in adolescents and young adults.

Authors:  Andrea C Villanti; S Elisha LePine; Catherine Peasley-Miklus; Julia C West; Maria Roemhildt; Rhonda Williams; William E Copeland
Journal:  Child Adolesc Ment Health       Date:  2022-03-06       Impact factor: 4.111

2.  Cumulative vulnerabilities as a potential moderator of response to reduced nicotine content cigarettes.

Authors:  Stephen T Higgins; Michael DeSarno; Janice Y Bunn; Diann E Gaalema; Adam M Leventhal; Danielle R Davis; Joanna M Streck; Roxanne F Harfmann; Catherine Markesich; Eva Orr; Stacey C Sigmon; Sarah H Heil; Jennifer W Tidey; Dustin Lee; John R Hughes
Journal:  Prev Med       Date:  2021-07-07       Impact factor: 4.637

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.